US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>AURN001, is an improved formulation designed to be mechanistically identical to Vyznova and to provide enhanced benefits, including manufacturing scalability and extended shelf life.</li>
<li>There is pending litigation between Aurion Biotech and the company's largest shareholder, Alcon Research.</li>
<li>This company is on a trajectory to set terms and debut in the first half of February.</li>
</ul>


AURN001, is an improved formulation designed to be mechanistically identical to Vyznova and to provide enhanced benefits, including manufacturing scalability and extended shelf life.
There is pending litigation between Aurion Biotech and the company's largest shareholder, Alcon Research.
This company is on a trajectory to set terms and debut in the first half of February.


Aurion Biotech (AURN):  Regenerative Eye Disease Biotech Filed for IPO Despite Investor Litigation